

*Amendments to the Claims*

This listing of claims will replace all prior versions and listings of claims.

Listing of Claims

1-5. (Canceled)

6. (Currently amended) ~~The method of claim 2, wherein the A method of stimulating angiogenesis in a mammal, comprising intramuscularly administering to said mammal an effective amount of adenoviral vector [[is]] pTG14550 (Pasteur Institute Deposit Number CNCM I-2695), deposited with the Pasteur Institute as deposit number CNCM I-2695.~~

7-42. (Canceled)

43. (Previously presented) The method of claim 6, wherein the mammal has ischemia.

44-47. (Canceled)

48. (Previously presented) The method of claim 6, wherein the mammal is treated for limb revascularization.

49. (Previously presented) The method of claim 48, wherein the limb is a leg.

50. (Previously presented) The method of claim 48, wherein the limb is an arm.

51. (Previously presented) The method of claim 6, wherein the mammal is human.

52. (Currently amended) The method of claim 6, wherein the ~~polynucleotide adenoviral vector~~ is administered with a pharmaceutically acceptable carrier selected from the group consisting of:

- (a) saline,
- (b) buffered saline,
- (c) dextrose,
- (d) water,
- (e) glycerol,
- (f) ethanol, and
- (g) combinations of the above.

53-56. (Cancelled)

57. (New) Adenoviral vector pTG14550 (Pasteur Institute Deposit Number CNCM I-2695).

58. (New) A pharmaceutical composition comprising the adenoviral vector of claim 57 and a pharmaceutically acceptable carrier selected from the group consisting of:

- (a) saline,
- (b) buffered saline,
- (c) dextrose,
- (d) water,
- (e) glycerol,
- (f) ethanol, and
- (g) combinations of the above.

59. (New) A method of treating ischemia in a mammal, comprising intramuscularly administering to said mammal an effective amount of adenoviral vector pTG14550 (Pasteur Institute Deposit Number CNCM I-2695).

60. (New) The method of claim 59, wherein the adenoviral vector is administered with a pharmaceutically acceptable carrier selected from the group consisting of:

- (a) saline,
- (b) buffered saline,
- (c) dextrose,
- (d) water,
- (e) glycerol,
- (f) ethanol, and
- (g) combinations of the above.

61. (New) A method of stimulating the migration of human dermal microvascular endothelial cells (HDMEC), comprising contacting said cells with an effective amount of adenoviral vector pTG14550 (Pasteur Institute Deposit Number CNCM I-2695).

62. (New) The method of claim 62, wherein said contacting is performed *in vitro*.